Skip to main content
Ipsen logo

Ipsen — Investor Relations & Filings

Ticker · IPN ISIN · FR0010259150 LEI · 549300M6SGDPB4Z94P11 PA Manufacturing
Open in API
Filings indexed 1,378 across all filing types
Latest filing 2017-07-25 Transaction in Own Shar…
Country FR France
Listing PA IPN

About Ipsen

https://www.ipsen.com/

Ipsen is a global biopharmaceutical company focused on innovation and specialty care. The company develops and commercializes transformative medicines to address high unmet medical needs in three key therapeutic areas: oncology, rare diseases, and neuroscience. By leveraging its specialized expertise and strategic partnerships, Ipsen aims to accelerate the development of new therapies and improve health outcomes for patients worldwide. Its strategy is centered on advancing science with purpose to bring innovative treatments from research and development to the market.

Recent filings

Filing Released Lang Actions
Rachat d'actions / Contrat de liquidité Descriptif du programme de rachat
Transaction in Own Shares Classification · 99% confidence The document text explicitly contains the heading "Déclaration des transactions sur actions propres réalisées du 17/07/2017 au 21/07/2017" (Declaration of transactions in own shares carried out from 07/17/2017 to 07/21/2017). This directly corresponds to the definition of a report detailing the company buying back or selling its own shares. This matches the 'Transaction in Own Shares' category (POS). The table shows daily transaction volumes and prices, confirming the nature of the filing.
2017-07-25 French
Communicated under the obligation to provide permanent information / Activity of the issuer (acquisition, sale, partnerships, etc.)
Earnings Release Classification · 95% confidence The document is a press release dated July 21, 2017, announcing that Ipsen received a positive opinion from the CHMP (Committee for Medicinal Products for Human Use) of the EMA regarding the approval of Xermelo® (telotristat ethyl). It details the results of Phase 3 trials (TELESTAR and TELECAST) and provides general safety information and background on the drug and the company. This type of announcement, which communicates significant clinical trial results and regulatory milestones (like a positive CHMP opinion leading to potential marketing authorization), is characteristic of an Earnings Release (ER) or a general press release related to business operations and product development. Since it focuses on the immediate announcement of a regulatory/clinical event rather than a comprehensive financial report (10-K, IR) or a transcript (CT), 'ER' (Earnings Release) is the most appropriate fit among the options for a major business update, even though it's not strictly tied to a quarterly earnings period. It is a major business/product announcement. FY 2017
2017-07-21 English
Communiqués au titre de l'obligation d'information permanente / Activité de l'émetteur (acquisitions, cessions, partenariats, …)
Regulatory Filings Classification · 95% confidence The document is a press release from Ipsen dated July 21, 2017, announcing that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion for the marketing authorization (MAA) of Xermelo® (telotristat ethyl). This announcement details clinical trial results (TELESTAR and TELECAST) supporting the drug's efficacy and safety for treating carcinoid syndrome diarrhea. This type of announcement, focusing on regulatory milestones (positive opinion leading to potential EU approval) and summarizing clinical data, is characteristic of a press release detailing significant corporate or product news, often preceding a formal filing or serving as an initial public disclosure. Since it is a detailed announcement of a major regulatory event and clinical data summary, it fits best under the 'Earnings Release' (ER) category if it were quarterly results, but here it is a specific regulatory/product update. Given the options, it is not a formal regulatory filing like a 10-K or IR, nor is it a transcript (CT) or a management discussion (MDA). It is a detailed announcement of a positive regulatory decision and supporting data. In the context of financial reporting categories, a major press release detailing clinical trial success and regulatory progress often aligns closely with an Earnings Release (ER) in terms of timing and purpose (disseminating key performance/progress indicators), or it could be considered a general Regulatory Filing (RNS) if no better fit exists. However, since it is a comprehensive announcement of a major drug approval milestone, it is most analogous to an Earnings Release (ER) which serves as the primary vehicle for material news dissemination, even if not strictly financial results. Given the strong focus on clinical/regulatory progress rather than just financial numbers, and lacking a specific 'Regulatory Approval Announcement' code, 'ER' is the closest fit for a major, detailed press release announcing material progress, or 'RNS' as a general regulatory announcement. Given the depth of the clinical data presentation, it leans more towards a substantive announcement than a simple RNS filing. I will classify it as an Earnings Release (ER) as it functions as the primary material news release for the period, even though it's not strictly earnings.
2017-07-21 French
Share buybacks / Liquidity contracts Description of share buyback program
Transaction in Own Shares Classification · 100% confidence The document explicitly states it is a 'Disclosure of transactions in own shares' and provides a table detailing daily volumes and weighted average prices for share buy-backs. This matches the definition for 'Transaction in Own Shares' (POS).
2017-07-18 English
Rachat d'actions / Contrat de liquidité Information relative au contrat de liquidité
Transaction in Own Shares Classification · 95% confidence The document is a semi-annual report regarding a liquidity contract (contrat de liquidité) for Ipsen shares managed by Natixis. It details the number of shares and cash held in the liquidity account as of June 30, 2017, compared to previous periods. This type of disclosure, which reports on the company's activity regarding its own shares under a liquidity agreement, is classified as a 'Transaction in Own Shares' (POS).
2017-07-18 French
Rachat d'actions / Contrat de liquidité Descriptif du programme de rachat
Transaction in Own Shares Classification · 99% confidence The document text contains a table detailing daily transactions ('Présentation agrégée par jour et par marché') and a clear heading: 'Déclaration des transactions sur actions propres réalisées du 10/07/2017 au 14/07/2017' (Declaration of transactions on own shares carried out from 07/10/2017 to 07/14/2017). This explicitly describes a report concerning the company buying back or selling its own shares. This directly matches the definition for 'Transaction in Own Shares' (Code: POS). The document is the declaration itself, not just an announcement of its publication.
2017-07-18 French

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.